CBG For Cancer And Pain?

This Cannabinoid Might Just Be The Next Big Thing In Marijuana

Cannabigerol (CBG) might be considered a minor cannabinoid, but it’s certainly garnering much more attention recently and it isn’t surprising why!

CBG, also known as the mother of all cannabinoids, is a lesser-known cannabinoid compared to its more famous siblings: CBD and THC. But as it occurs as a precursor to CBD and THC, enzymes convert cannabigerolic acid into these other cannabinoids. As a result, mature cannabis plants only contain trace amounts of CBG in them. However, researchers have found that there’s a good reason or two to use CBG for health and wellness.

Studies Show Potential Anti-Cancer Mechanisms In CBG

According to a recent article in Marijuana Moment, scientists found that CBG could even have potential benefits for treating cancer, pain, and inflammatory conditions.  Through a review of studies, researchers from China and the United States worked together to review the effects of the cannabinoid, as well as its impacts on the body.

“CBG has emerged as a potential therapeutic agent with a diverse range of effects,” reads the study. “Although this research on CBG is still in its early stages, its unique molecular mechanism and promising therapeutic profile warrant further exploration,” they said.

“As research progresses, CBG presents a promising therapeutic agent with a unique molecular profile and a broad spectrum of potential benefits,” said the researchers. “As we deepen our understanding of CBG, it may lead to breakthroughs in treating complex conditions, ultimately improving patient outcomes and expanding the scope of cannabinoid-based medicine,” it wrote.

Researchers also found that it could be beneficial in reducing pain. They observed that administering CBG was helpful in decreasing pain sensitivity on animal subjects. “This research unveils a potential mechanism for CBG’s indirect neuroprotective effects. By reducing pain signaling in the nervous system, CBG might offer relief from chronic pain conditions,” said the researchers. “This finding adds to the growing body of evidence suggesting CBG’s potential role in protecting the nervous system by managing pain.”

In another study also from 2024, scientists acknowledge the anti-cancer properties of cannabinoids including CBD, THC, and even CBG. “Cannabinoids, including 9-THC, CBD, and CBG exhibit significant anticancer activities such as apoptosis induction, autophagy stimulation, cell cycle arrest, anti-proliferation, anti-angiogenesis, and metastasis inhibition,” wrote the report.

“Clinical trials have demonstrated cannabinoids’ efficacy in tumor regression and health improvement in palliative care,” they wrote. That said, the researchers acknowledge that more work needs to be done to understand the cannabinoids’ mechanism of action for these. “Despite the evident anti-cancer properties of cannabinoids from numerous experimental results, the exact mechanisms of action still require extensive research,” they said.

These, and several other studies, note the promising efficacy and safety of CBG for treating cancer especially when used in conjunction with other cannabinoids. Typically, these studies also look at CBD and THC. After all, it’s a well-known fact that the entourage effect is more powerful than isolating cannabinoids alone. It refers to the synergistic interactions between cannabinoids as well as the other compounds found in marijuana.

Simply put, the entourage effect states that the therapeutic benefits of cannabinoids are much more powerful when they all work together instead of just one alone. In these studies, we can see that CBG may be a potent anti-cancer compound particularly when given to patients alongside CBD and THC.

CBG For Colorectal Cancer

Meanwhile, another study from 2014 highlighted CBG’s potential for treating colorectal cancer. The study, which was published in the medical journal, Carcinogenesis, discusses the powerful action observed where CBG  promotes programmed cell death (apoptosis). In addition, the scientists observed that CBG was also beneficial in improving oxidative stress response while reducing the cancer cell growth.

CBG with Other Cannabinoids For Breast Cancer

In a 2018 study, researchers analyzed the anti-tumor activity observed in different types of cancer when exposed to various botanical preparations containing cannabinoids such as THC, THCA, and CBG. They found that the preparations containing all these cannabinoids were much more powerful than those containing just THC for breast cancer, of course due to the entourage effect. The researchers concluded that these drug preparations were indeed more powerful than just simply pure cannabinoids.

CBG For Tumors

Glioblastoma is one of the most difficult cancers to treat. It’s also extremely aggressive, and patients with this form of cancer are given just about a year more to live. Since glioblastoma is so difficult to treat, it usually requires radiation, chemotherapy, as well as surgery.

There have been several studies pointing to the numerous benefits of THC for glioblastoma, but now scientists see the potential of CBG as well. In February 2021, the results of a significant study on CBG and glioblastoma was released. Researchers from the University Medical Centre Ljubljana studied biopsied glioblastoma tumor cells as well as glioblastoma stem cells from patients with this type of cancer. For this study, the researchers analyzed the anti-tumor properties of different cannabinoids and doses, including THC, CBD, and CBG. They also compared the results of cannabinoids with temozolomide.

They found that CBG was effective in making glioblastoma more responsive to chemotherapy, when used alone or together with CBD. As a result, this yielded better rates of apoptosis. Furthermore, they found that combining CBD and THC was effective in reducing the viability of both cell types and promoted a significant degree of apoptosis among glioblastoma cells.

They also found that CBG worked to inhibit as much as 90% of invasive glioblastoma cell tendril development, whereas chemotherapy drugs only worked for 50%. These are extremely important findings since glioblastoma cell tendrils are extremely invasive, a major reason why this cancer is nearly impossible to treat. “THC has little added value in combined-cannabinoid glioblastoma treatment, suggesting that this psychotropic cannabinoid should be replaced with CBG in future clinical studies of glioblastoma therapy,” they added.

CONCLUSION

 

CBG should no longer be viewed as a ‘minor cannabinoid’. With all its potential health benefits, especially in the realm of cancer, this life-saving cannabinoid can help improve the prognosis and lifespan for thousands of cancer patients worldwide. We hope to see more studies cementing its therapeutic applications for cancer.

CBG FOR PAIN RELIEF, READ ON…

WHY IS CBG BEING TESTED FOR PAIN RELIEF MEDS?

The Leveling-Out Has Begun

When Colorado and Washington made history by fully legalizing recreational cannabis in 2012, the industry exploded like a champagne bottle that had been shaken for decades.

Sales surged almost immediately—and why wouldn’t they? Something that had been villainized and pushed into the shadows for generations was suddenly available at clean, well-lit stores with knowledgeable staff. No more texting sketchy dealers or meeting in parking lots. No more “my guy is running late” or “all I’ve got is this mysterious brown stuff.” Americans could finally buy cannabis products with the same ease as picking up a bottle of wine.

This green gold rush continued as legalization spread across the country. New markets opened in Oregon, California, Massachusetts, and beyond, each experiencing their own initial boom as consumers celebrated their newfound freedom. Cannabis businesses sprouted like, well, weeds. Investors poured billions into the sector, expecting an endless upward trajectory.

But something interesting has been happening over the past year or two. After watching this market for the past 15 years, I’ve observed a distinct “leveling-out” in 2024. The explosive growth has given way to a more sobering reality. In mature markets like Colorado, sales have actually declined significantly from their peaks. The industry isn’t collapsing by any means, but that initial euphoria has faded.

Today, we’re diving deep into this cannabis market cooldown. What’s causing this plateau? Is it market saturation, changing consumer habits, pricing pressures, or perhaps broader economic forces? And what can we expect moving forward, especially with the political shitfuckery surrounding cannabis policy at the federal level? Will the DEA’s potential rescheduling of cannabis to Schedule III change the game, or is it just another half-measure that misses the point?

Grab your favorite strain and settle in—we’ve got a lot to unpack.

Let’s face it—cannabis has undergone one of the most dramatic image rehabilitations in American cultural history. What was once depicted as a gateway to madness and moral decay in films like “Reefer Madness” is now casually discussed at dinner parties and openly consumed by celebrities on podcasts. These days, most people across the political spectrum support cannabis legalization in some form. The social stigma hasn’t completely vanished, but it’s fading faster than your memory after hitting a potent indica.

Sure, you still have your occasional media hit pieces about “today’s super-potent weed,” and there’s no shortage of conservative cucks who believe they should dictate what sovereign human beings can put into their own bodies. They’ll raise hell about the “dangers” of legalization while sipping their third bourbon of the evening. But these voices are increasingly drowned out by common sense and empirical evidence.

The truth is that the majority of Americans no longer consider cannabis to be more dangerous than beer. And if Budweiser can drop $7 million on a 30-second Super Bowl ad featuring talking frogs, then bowls of cannabis should be legally available to adults without controversy. This widespread acceptance is a double-edged sword for the industry, though.

When cannabis was first legalized, there was an undeniable electricity in the air. Hardcore stoners who had been advocating for decades were vindicated and celebrated. Curious newcomers who had been cannabis-curious but law-abiding finally had the opportunity to try it in a safe, legal environment. The euphoria of legalization was palpable, almost like fresh lovers high on endorphins and serotonin, eagerly exploring this new terrain of freedom.

However, as with any puppy love, that initial intensity eventually mellows. The novelty wears off. What was once exciting becomes routine. Similarly, the novelty of legal cannabis has faded into normalcy. The “I can’t believe this is actually happening” factor has been replaced with “Yeah, I might stop by the dispensary later, no big deal.”

I hate to break it to you all, but cannabis is now as mainstream as it gets. From soccer moms using tinctures to manage anxiety to lawyers unwinding with a vape pen instead of a martini, cannabis has infiltrated every demographic. College professors, construction workers, retirees, tech entrepreneurs—cannabis use cuts across all social boundaries. It’s just not that edgy or counterculture anymore.

As a result, the cultural force that was driving the cannabis industry in its inception has lost some power. Many consumers assume it’s a done deal—cannabis is legal, accessible, and here to stay. But this complacency is dangerous.

And that’s something we definitely need to address—until cannabis is completely removed from the Controlled Substances Act, nothing is set in stone. Federal prohibition still creates enormous problems for the industry, from banking restrictions to research limitations to inequities in enforcement. Just because you can walk into a dispensary doesn’t mean the battle is over.

The waning of novelty may be inevitable, but the fight for full legalization and normalization continues, even as we browse dispensary menus with the same casual interest we once reserved for Netflix titles.

The cannabis industry’s slowdown in 2024 wasn’t just about market maturation—it was also heavily influenced by the presidential election hanging over everything like a thick cloud of uncertainty. It’s pretty much a given that during presidential election years, cannabis reform tends to stall out as legislators and regulators become hyper-focused on election results and avoiding controversial moves.

The 2024 election was particularly paralyzing due to the vast ideological divide splitting the country. When Donald Trump reclaimed the White House to become the 47th president, the cannabis industry collectively held its breath. After all, the Biden administration had set various cannabis reform wheels in motion—however slowly they were turning—with the DEA’s recommendation to reschedule cannabis to Schedule III being the most significant.

With Trump’s victory, everything suddenly went into freeze-frame. Industry players, investors, and advocates all found themselves stuck in a waiting game, unsure how the new administration would approach cannabis policy. Would Trump honor the rescheduling process already underway? Would he reverse course completely? Nobody knew for certain.

I already told you all that Schedule III was dead on arrival, but the situation is even more complex when you consider who really came into power with Trump. People weren’t just voting for Trump—they were voting for the influence of Elon Musk, Tulsi Gabbard, RFK Jr., and others who have Trump’s ear. That’s why I call him “President Trusk”—because arguably Musk has unprecedented influence over the president’s policies and worldview.

I could go down a deep, dark conspiracy rabbit hole about all of this, but let’s stay focused on the cannabis stuff. What matters is that the industry is now recalibrating and gauging their next steps. We know that Schedule III will likely be blocked or abandoned, and that the only viable path forward is legalization via Congress. However, while that lengthy process plays out—if it even begins—state-by-state legalization must continue to build momentum.

The stark reality is that the next four years will be a roller coaster of unpredictable policies and political maneuvering. Most Americans will be so fixated on the broader cultural and political battles that cannabis reform may fade from the spotlight. The media cycle will be dominated by whatever outrageous tweet or policy announcement comes next, not by incremental changes to state cannabis programs.

I personally have no idea how it’s going to play out, and any analyst who claims they do—unless they have insider information—is lying through their teeth. We’re in uncharted territory with no reliable map.

The truth is that we’re in a weird spot. Without more states legalizing cannabis or expanding their existing programs, the federal government will have little incentive to pursue meaningful reform. The industry’s growth may continue to plateau until there’s a clear signal from Washington.

And let’s not forget, Trump promised the death penalty for drug dealers during his campaign. Will that extreme stance apply to all drugs or just fentanyl? Could the United States become an even more dangerous place for those involved in any aspect of drug policy? The uncertainty alone is enough to make investors hesitant and consumers anxious.

The post-election cannabis landscape isn’t just leveling out—it’s holding its breath, waiting to see which way the wind blows from the White House.

THE SATURATED CANNABIS MARKET, READ ON…

CANADA HAS TOO MUCH CANNABIS, OVER 3 MILLION POUNDS EXTRA!

Which Severe Mental Disorders Can Psychedelics Help With?

Severe mental illnesses refer to conditions that leave the patient with significant functional impairment and extreme symptoms. Sometimes, these may include serious symptoms such as psychosis, which can have harmful consequences if they aren’t diagnosed and treated early on.

Common treatments for serious mental health disorders vary; they usually include a combination of somatic and psychotherapeutic treatments. When it comes to medications, these can include antidepressants, antipsychotics, mood stabilizers, and anti-anxiety medications. Severe cases of depression may require neurofeedback, and other brain stimulation therapies to work. Until now, there is no one-size fits-all solution for mental health disorder treatments; many patients usually find success, if any, in using a combination of therapies for many years – sometimes, for life.

In fact, many patients even develop a tolerance to medications. This can make it difficult to find drugs that work, yet even then, most medications come with unwanted side effects.

But the rise of psychedelic use has brought about promise for those struggling with mental health problems, and their families. No other medication can induce psychological and neurobiological changes the way psychedelics can, thereby improving cognitive function and emotional processing. Psychedelics activate serotonin receptors, enhance neuroplasticity, and disrupt the default mode networks that cause rigid thinking and worsen depression. Because of this, psychedelics are considered a revolutionary treatment for severe mental health conditions that are resistant to treatment.

Check out this list of severe mental health disorders, and how psychedelics can help treat them.

Schizophrenia

Schizophrenia is a severe, chronic mental health disorder that greatly affects the way a person thinks, behaves, and fees. The main symptom of schizophrenia is a serious disconnection and detachment from reality, which can manifest through symptoms of psychosis. These may include delusions, hallucinations, disorganized behavior, and disorganized thinking.

Schizophrenia can be extremely challenging to treat and manage due to many factors, most especially the fact that the symptoms drastically differ from one patient to another. Also, many individuals with this condition don’t respond to conventional treatment.

Many studies have shown that psychedelics are promising for treating schizophrenia and managing its symptoms, allowing patients to regain control and enjoy a better quality of life. That said, it must be acknowledged that small doses of psychedelics are needed because larger doses may have negative effects. Keeping the doses at a clinically accepted low level can induce powerful anti-inflammatory properties especially benefiting patients’ brain function.

Additionally, regulated doses have been found to be well-tolerated and effective in treating several mental illnesses, including schizophrenia, which is notoriously difficult to treat.

Borderline Personality Disorder

Borderline personality disorder or BPD is a very complex mental health disorder whose hallmark symptoms include unstable relationships, severe emotional dysregulation, and constant impulsive actions. For this reason, it can also be known as emotionally unstable personality disorder. Some severe cases include high suicidal tendencies.

Successful treatment can feel like an uphill battle, as many patients often drop out. It has become critical to develop new treatments for BPD which have less side effects, and are certainly much more effective.

However, some research has pointed to psychedelic therapy. In one study in particular, authors found that MDMA combined with psychotherapy is effective and safe for treating borderline personality disorder. Researchers found that it provides a safe and beneficial alternative even for treating chronic PTSD, a co-occurring disorder of BPD. The researchers also found that MDMA was effective even when administered just twice or thrice during the course of a treatment, whereas psychotropic drugs commonly prescribed in psychiatry often must be taken everyday for a certain period of time.

The treatment, known as MDMA-assisted psychotherapy, is gaining traction for treating other complex mental health disorders as well.

Severe Anxiety Disorders

Severe anxiety disorders significantly impact the daily life, as well as quality of life, of patients. Whereas generalized anxiety disorders may be occasional bouts of anxiety, severe anxiety is intense, persistent, and chronic.

Patients with severe anxiety disorders excessively ruminate and worry about things that often can’t be controlled, even without a trigger. It can manifest physically, such a through hyperventilation, shakes, sweating, and a racing heart. Long term effects include insomnia, headaches, fatigue, and difficulty thinking straight. The severe anxiety is so debilitating that it requires serious and professional interventions for patients to regain their quality of life.

Thankfully, a handful of various psychedelics have shown promising results for treating severe anxiety disorders, even where conventional medications have failed. Psilocybin is one of the most widely studied psychedelics for treating chronic anxiety; studies show that it has long-lasting results in anxiety management, with excellent results observed months even after the last treatment.

LSD (lysergic acid diethylamide), or also known as acid, has also been widely studied for mental health disorders especially anxiety. According to studies, LSD can enhance cognitive flexibility and reduce anxiety scores especially when used in psychotherapy. As a result, patients can break rigid mental thought patterns that can influence anxiety-driven behaviors. LSD interacts with serotonin receptors in the brain, such as 5-HT1A and many others, which help regulate mood and reduce anxious behaviors.

MDMA’s potential for treating anxiety and other mental health disorders likewise continues to grow. Patients who struggle with anxiety show positive responses to MDMA; it has been shown to strengthen emotional processing while improving the coping mechanisms of patients. Also known by its street drug names molly or ecstasy, MDMA works well in modulating neurotransmitters in the brain, including dopamine, serotonin, and norepinephrine. These all play an important role in regulating one’s emotions and improve overall mood.

CONCLUSION

If you or a loved one are struggling with mental health disorders and would like to experiment with psychedelics, it’s always recommended to do so in a clinical setting. These are not conditions wherein self-medicating is advisable, because of the harmful side effects of taking too much or too little, as well as the potential interactions of psychedelics with other medications.

Therapy sessions in a controlled environment is the best, safest way to medicate with psychedelics for severe mental health disorders. Reach out to a medical professional to get started, but do your own research.

PSYCHEDELICS FOR MENTAL HEALTH DISORDERS, READ ON..

PSYCHEDELICS WITHOUT TRIPPING, A MENTAL HEALTH BREAKTHROUGH?